Catalyst Biosciences Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Catalyst Biosciences's estimated revenue is currently $0M per year.
- Catalyst Biosciences received $115.0M in venture funding in February 2018.
- Catalyst Biosciences's estimated revenue per employee is $122
- Catalyst Biosciences's total funding is $94.3M.
- Catalyst Biosciences has 49 Employees.
- Catalyst Biosciences grew their employee count by 20% last year.
- Catalyst Biosciences currently has 9 job openings.
|Jen Wilson||Director, Project Management|
|Janet Hillman||Senior Director Project Management|
|Veronica Cai||Senior Director, Controller|
|Eddie Williams||Board of Directors|
|Arwa Shurrab||Vice President|
|Faisal Shawwa||Executive Director Finance & Senior Controller|
|Andy Howe||Sr Director Quality Assurance|
|Andrew Hetherington||SVP Technical Operations|
|Rene Alvarez||Director, Medical Writing|
|Frank Booth||Consultant Clinical Development Director|
What Is Catalyst Biosciences?
Catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. We used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. Learn more about Our Hemophilia Program. A protease is an enzyme that cleaves target proteins. Learn more about Proteases.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$25.7M||178||8%|
|Full Spectrum A...||$6M||42||5%|
Catalyst Biosciences News
Catalyst Biosciences to Present at the 2019 ASBMB Symposium on Serine Proteases in Pericellular Proteolysis and Signaling Conference ...
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced an oral ...
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that its ...
Catalyst Biosciences Funding
|2008-12-04||$40.4M||C||Essex Woodlands Health Venture||Article|
|2017-04-10||$20.7M||Undisclosed||Ladenburg Thalmann & Co. Inc||Article|
|2017-12-22||$10.5M||Undisclosed||JonesTrading Institutional Services LLC||Article|
|2018-02-14||$115.0M||Undisclosed||JonesTrading Institutional Services LLC||Article|
Catalyst Biosciences Executive Hires
|2005-03-09||Title: David J. O'Reilly||President||Article|
|2006-02-13||Edwin Madison||Chief Scientific Officer||Article|
|2006-05-24||Marc Navre||VP Drug Discovery||Article|
|2007-02-02||Erik Wiberg||Chief Financial Officer||Article|
|2008-10-29||Todd Lorenz||Chief Medical Officer||Article|
|2010-03-03||William J. Dawson||CFO||Article|
|2017-02-17||Andrew Hetherington||SVP Technical Operations||Article|
Catalyst Biosciences Staff Cuts
|Date||Number of Employees||Location||Reference|